Effect of a tart cherry juice supplement on arterial stiffness and inflammation in healthy adults: a randomised controlled trial. by Lynn, Anthony et al.
Effect of a tart cherry juice supplement on arterial stiffness 
and inflammation in healthy adults: a randomised 
controlled trial.
LYNN, Anthony, MATHEW, Shilpa, RUSSELL, Jean, ROBINSON, Emma, 
SOUMPASI, Vithleem and BARKER, Margo
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/8524/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
LYNN, Anthony, MATHEW, Shilpa, RUSSELL, Jean, ROBINSON, Emma, 
SOUMPASI, Vithleem and BARKER, Margo (2014). Effect of a tart cherry juice 
supplement on arterial stiffness and inflammation in healthy adults: a randomised 
controlled trial. Plant Foods for Human Nutrition, 69 (2), 122-127. 
Repository use policy
Copyright © and Moral Rights for the papers on this site are retained by the 
individual authors and/or other copyright owners. Users may download and/or print 
one copy of any article(s) in SHURA to facilitate their private study or for non-
commercial research. You may not engage in further distribution of the material or 
use it for any profit-making activities or any commercial gain.
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
 1 
Effect of a tart cherry juice supplement on arterial stiffness and inflammation in 1 
healthy adults: a randomised controlled trial. 2 
Anthony Lynn1., Shilpa Mathew2., Chris T Moore2., Jean Russell3., Emma Robinson2., 3 
Vithleem Soumpasi2., Margo E Barker2.. 4 
1. Food and Nutrition Group, Sheffield Business School, Sheffield Hallam University S1 5 
1WB, 2. Human Nutrition Unit, Department of Oncology, School of Medicine, University of 6 
Sheffield, S10 2RX  3. CICS, University of Sheffield S10 2HB 7 
  8 
Corresponding author: Anthony Lynn T.Lynn@shu.ac.uk; Tel: ++44 (0)114 2252065; fax: 9 
++44 (0)114 2255036.  10 
Abbreviations used: BP, blood pressure; BMI, body mass index; CV, coefficient of variation; CRP, 11 
c-reactive protein; DBP, diastolic blood pressure; FRAP, ferric reducing-antioxidant power; HDL, 12 
high density lipoprotein; PWV, pulse wave velocity; SBP, systolic blood pressure; SD, standard 13 
deviation. 14 
 15 
Keywords: cherry, arterial stiffness, inflammation, blood pressure. 16 
 17 
Abstract 18 
Tart cherries are a particularly rich source of anthocyanins. Evidence indicates that dietary 19 
intake of anthocyanins is inversely associated with arterial stiffness. We conducted an open-20 
label randomised placebo controlled study to determine whether a tart cherry juice 21 
concentrate (Cherry Active®) reduced arterial stiffness, inflammation and risk markers for 22 
cardiovascular disease in 47 healthy adults (30 – 50 y). Participants consumed 30 ml of 23 
cherry concentrate diluted to a volume of 250 ml with water or the same volume of an energy 24 
matched control drink daily for 6 weeks. Measurements were taken at baseline and at the end 25 
of the intervention. There was no effect of the intervention on arterial stiffness (P=0.218), c-26 
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reactive protein (P=0.220), systolic blood pressure (P=0.163), diastolic blood pressure 27 
(P=0.121), total cholesterol (P=0.342) and high density lipoprotein cholesterol (P=0.127). At 28 
the end of the intervention, plasma antioxidant capacity (measured as the ferric reducing 29 
ability of plasma (FRAP) was significantly higher in the intervention group than the control 30 
group (P=0.012). We conclude that a tart cherry juice concentrate rich in anthocyanins has no 31 
effect on arterial stiffness, c-reactive protein and risk markers for cardiovascular disease, but 32 
evokes a minor increase in antioxidant status in healthy adults.  33 
 34 
Introduction  35 
Epidemiological studies indicate that the consumption of foods rich in flavonoids reduces the 36 
risk of cardiovascular disease, with some evidence that anthocyanins may be particularly 37 
protective [1-3].  Cherries are a rich source of flavonoids, especially anthocyanins [4-5]. In 38 
cell culture and animal models, cherry extracts or isolated anthocyanins have been shown to 39 
exert a range of potentially cardioprotective effects including, increasing nitric oxide 40 
production and antioxidant status, reducing lipid oxidation and inhibiting inflammation [6-9]. 41 
Anti-inflammatory effects have also been reported in a limited number of human studies [10-42 
13]. In healthy middle-aged adults, the daily consumption of sweet cherries for 4 weeks 43 
reduced several markers of inflammation [10, 11]. Also, supplementation with tart cherry 44 
juice reduced exercise-induced inflammation in marathon runners and in adults completing a 45 
resistance exercise task [12, 13]. 46 
There is interest in whether diets rich in dietary anthocyanins can reduce arterial stiffness 47 
and therefore risk of cardiovascular disease [14]. Arterial stiffness is determined by the 48 
structural properties of the arterial wall, blood pressure and endothelial function [15]. Some 49 
experimental evidence indicates that anthocyanins can improve endothelial function via 50 
induction of endothelial nitric oxide synthase, so by extrapolation anthocyanins may reduce 51 
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arterial stiffness [16, 17]. In patients with hypercholestrolaemia, endothelial function was 52 
improved by a single dose of anthocyanins (320 mg) and a period of chronic supplementation 53 
(320 mg/d x 12 weeks) [17]. In the chronic supplementation study, endothelial function was 54 
improved > 12 hours after consumption of the last dose of anthocyanins when intact 55 
anthocyanins and their metabolites could not be detected in the plasma of participants. The 56 
authors speculated that anthocyanins may have accumulated in tissues [17].    57 
In a cross-sectional study of women from the TwinsUK registry, arterial stiffness was 58 
inversely associated with anthocyanin intake, but not with total flavonoid intake [14]. The 59 
risk of residual confounding means that casual inference cannot be ascertained from cross-60 
sectional studies, so intervention studies are needed to demonstrate that anthocyanin rich 61 
foods can reduce arterial stiffness [14].  In a recent study, daily supplementation with 62 
cranberry juice (rich in anthocyanins; 94 mg/d) for 4 weeks reduced arterial stiffness in 63 
overweight adults with coronary artery disease [18]. The effect of anthocyanin rich foods on 64 
arterial stiffness in healthy adults remains largely unexplored. In the present study we aimed 65 
to determine whether a commercial tart cherry juice concentrate rich in anthocyanins reduced 66 
arterial stiffness, inflammation and other markers of cardiovascular risk in healthy adults.      67 
 68 
METHODS 69 
Participants A total of 47 (29 female and 18 male) apparently healthy, non-smoking 70 
volunteers (age 30-50 y) were recruited through University email distribution lists, posters 71 
and personal contacts. Exclusion criteria included taking medication for heart disease, 72 
hypertension or diabetes, regular consumption of cherries or cherry juice and the use of 73 
antioxidant supplements. The study was approved by Sheffield Hallam University Ethics 74 
Committee and all volunteers gave written informed consent. The study was conducted 75 
between May 2010 and August 2011. 76 
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Study design. The study was a 6-week parallel open-label intervention of a daily supplement 77 
of cherry juice concentrate (30 ml diluted with 220 ml of water; Cherry Active®) versus a 78 
control drink of lemonade (250 ml/d; Sprite®). Both drinks were delivered to participants at 79 
the start of the intervention; those consuming the cherry juice were instructed to store the 80 
juice in their refrigerators before consumption. The concentrated cherry juice was dispensed 81 
automatically using a pump-action dispenser from a 950 ml bottle, whilst the lemonade was 82 
supplied in individual 250 ml bottles.  Participants consumed the drinks during the day, 83 
according to their preference.  84 
Participants were stratified by gender and age (30-39 years and > 40 years) and then 85 
block randomised to treatment by an investigator who was not involved in recruitment.   86 
Concealed envelopes were used to inform the researchers responsible for recruitment of the 87 
treatment allocation; this information was not made available until after baseline 88 
measurements were completed.  Compliance to the intervention was recorded through 89 
participants keeping a daily tick-sheet of drinks consumed.   It was emphasised to all 90 
participants that they should adhere to their usual diet and maintain usual exercise patterns in 91 
conjunction with daily consumption of the test drinks.  92 
Our primary outcome variable was change in pulse wave velocity (PWV); our 93 
secondary outcome variable was change in c-reactive protein (CRP).  Power calculations 94 
were based on a 10% change in PWV.  A sample size of 50 (25 per arm) was calculated to 95 
detect a 10% change in PWV with 80% power and an alpha value of 0.05, using variance 96 
estimates of PWV (SD = 1.06, n=57) from a study of PWV (unpublished data).   97 
Tart cherry juice concentrate and placebo beverage 98 
The tart cherry juice concentrate was supplied by Cherry Active, Sunbury UK. A 30 ml 99 
serving of tart cherry juice was diluted with 220 ml of water prior to consumption. Each 100 
serving was estimated to contain the equivalent of 90-100 Montmorency tart cherries. The 101 
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composition of the juice was analysed by an independent laboratory (Atlas Bioscience Inc, 102 
Tuscan, AZ, USA). Each 30 ml serving of the concentrate contained 102 kcal, 24.5 g 103 
carbohydrate, 1.1 g protein, trace amounts of fat, 2.6 g fibre, 9.72 mg ascorbic acid, 408 µg β-104 
carotene and trace amounts of sodium. The total anthocyanin content per serving was 273.5 105 
mg. The predominant anthocyanins normally present in tart cherries are cyanidin derivatives 106 
with smaller amounts of peonidin-3-rutinoside. Other compounds typically present include 107 
hydroxycinnamic acids, flavonols and the indoleamine, melatonin [4, 19, 20]. The very 108 
distinctive taste of the cherry concentrate made it difficult to blind the study. The placebo 109 
beverage (Sprite®, The Coca-Cola Company) was chosen because it closely matched the 110 
energy and macronutrient composition of cherry juice (109 kcal, 26.4 g CHO, 0 g fat, 0.1 g 111 
sodium per 250 ml) and was devoid of plant compounds, antioxidants and vitamins. 112 
Measurements Participants attended Sheffield Hallam University on two occasions for 113 
vascular measurements, anthropometric measurements and blood sampling. All these were 114 
taken in the early morning after an overnight fast. On both occasions, PWV, systolic blood 115 
pressure (SBP), diastolic blood pressure (DBP) and body weight were measured and a blood 116 
sample was taken. Height was also measured at the baseline visit. Measurements were taken 117 
after a 15 min rest in the supine position to allow time for BP, cardiac function and 118 
vasomotor tone to reach resting levels.  119 
Brachial-knee PWV was measured in the supine position using a Nicolet Vasoguard 120 
Microlight system (VIASYS Healthcare, USA) as previously described [21].  BP and heart 121 
rate were measured in triplicate at 2.5 min intervals in the supine position using a semi-122 
automated Accutorr Plus™ sphygmomanometer (Datascope®, USA). The first reading was 123 
disregarded to prevent readings being affected by the defence mechanism (the rise in BP 124 
associated with anxiety of measurement, that tends to subside with subsequent 125 
measurements) [22] and mean SBP, DBP and heart rate were calculated from the second and 126 
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third measurements. The Accutorr Plus™ sphygmomanometer was calibrated prior to the 127 
start of the study. The device meets the US Association for the Advancement of Medical 128 
Instrumentation and British Hypertension Society criteria for accuracy and has been 129 
recommended by the European Society of Hypertension [23]. 130 
Weight was measured to the nearest 0.1 kg using a SECA 709 mechanical column 131 
scale and height was measured to the nearest 0.1 cm with a SECA 220 telescopic measuring 132 
rod (SECA, Birmingham, UK). 133 
Fasting capillary blood samples were collected for the determination of total 134 
cholesterol, high density lipoprotein (HDL) cholesterol, CRP and total antioxidant activity 135 
(ferric reducing ability of plasma; FRAP). Lipid variables were measured on a Reflotron Plus 136 
reflectance photometer (Roche Diagnostics Ltd, Burgess Hill, UK). For the analysis of total 137 
cholesterol a 30 µl sample of whole blood was collected into a capillary pipette and applied 138 
to a Reflotron reagent strip (Inverness Medical, Stockport, UK). The within day precision 139 
was 0.8% and the between day precision was 1.2%. For the determination of HDL, a 60 µl 140 
sample of whole blood was collected into an EDTA-potassium coated microcentrifuge tube 141 
(Sarstedt Ltd, Leicester, UK) and spun at 2000 g x 5 min. Plasma was then extracted and 142 
applied to a Reflotron HDL cholesterol strip (Inverness Medical, Stockport, UK) for 143 
immediate analysis. The within day precision was 7.0% and between day precision was 8.3%.   144 
A 250 µl whole blood sample was also collected into a lithium-heparin coated 145 
microcentrifuge tube (Sarstedt Ltd, Leicester, UK) and spun at 2000 g for 10 min at 4oC to 146 
extract plasma.  The plasma was divided into two aliquots. One aliquot was stored at -80oC 147 
for the later analysis of CRP and the second aliquot was used for the immediate 148 
determination of plasma antioxidant activity (FRAP). FRAP was measured as described by 149 
Benzie and Strain [24] on a Cecil Series 1000 UV/Vis spectrophotometer (Cecile Instruments 150 
Ltd, Cambridge, UK). The intra-assay coefficient of variation (CV) was 1.4% and the inter-151 
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assay CV was 4.2%.  Plasma CRP was measured using a commercially available ELISA kit 152 
(MP Biomedicals UK, Cambridge, UK).  The intra-assay CV was 11.5% and the inter-assay 153 
CV was 12.3%. 154 
Statistical analysis For each variable, analysis was restricted to participants for whom 155 
baseline and end of study data were available (see Table 2 for n values). The effect of 156 
treatment on post-intervention measures was analysed by a one way ANCOVA, with 157 
adjustment for baseline [25].  The residuals from the model were tested for normality using 158 
the Shapiro-Wilk test and log transformation was used when there was deviation from 159 
normality.  The criterion for significance was a P<0.05.   All analyses were conducted using 160 
SPSS version 20.0 (SPSS UK Ltd. Woking, UK).  161 
 162 
Results  163 
Baseline characteristics, retention and compliance Anthropometric, biochemical and 164 
vascular measures were similar in randomisation groups at baseline (Table 1 & 2) and the 165 
groups were balanced for sex and age. One participant withdrew from the study because they 166 
did not like the taste of the cherry juice; all other participants completed the intervention 167 
without report of adverse effects. Compliance to the intervention was good with 97% of 168 
drinks consumed by the cherry juice group and 98% of drinks consumed by the placebo 169 
group.  170 
Effect of intervention   There was no significant difference between the groups for the 171 
primary outcome variable of PWV (Table 2).  Cherry juice did not have any effect on CRP, 172 
SBP, DBP, total cholesterol or HDL cholesterol relative to the placebo drink (Table 2). 173 
Antioxidant status was significantly elevated at the end of the intervention in the cherry juice 174 
group compared to the placebo group (P=0.012). In comparison to the cherry juice group 175 
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there was a weak trend towards an increase in bodyweight in the placebo group (adjusted 176 
mean difference 0.69 (95% CI -0.07, 1.15) kg; P=0.073).  177 
 178 
Discussion  179 
There is some evidence from dietary observational studies that anthocyanin intake is 180 
associated with PWV – a large study of 1872 women from the TwinsUK registry reported 181 
that women with a high intake of dietary anthocyanins had lower PWV [14].  The present 182 
study was designed to test the hypothesis that short-term dietary intervention with 183 
anthocyanins supplied as tart cherry juice would reduce PWV and a range of other risk 184 
markers for CVD in healthy adults. To our knowledge no other study has investigated the 185 
effect of tart cherry juice on PWV. However, Dohadwala et al. [18] reported that a 4-week 186 
intervention with double strength cranberry juice (supplying 94 mg/d of anthocyanins) 187 
reduced carotid-femoral PWV (by approximately 0.5 m/s) in overweight adults with coronary 188 
artery disease. Despite providing approximately 3 times the quantity of anthocyanins to our 189 
participants we failed to observe a reduction in PWV. Differences in study design may 190 
explain this discrepancy. Dohadwala et al. [18] studied a group of overweight adults with 191 
elevated risk markers for cardiovascular disease, whereas our volunteers had a normal body 192 
mass index (BMI) (approx. 24 kg/m2) and were seemingly healthy. It is possible that in 193 
healthy individuals, arterial stiffness is less responsive to a short-term increase in the intake 194 
of anthocyanins. Moreover we measured brachial-knee PWV, which because it includes 195 
segments of peripheral muscular arteries may be less amenable to dietary intervention than 196 
carotid-femoral PWV. It is also possible that constituents of cranberry juice other than 197 
anthocyanins may have driven the reduction in PWV observed by Dohadwala et al. [18].    198 
The influence of supplementation with drinks rich in other polyphenolic compounds such as 199 
green tea (rich in flavanols) [26] and pomegranate juice (rich in elagitannins but also a source 200 
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of anthocyanins) have also shown no effect on arterial stiffness [21], whilst supplementation 201 
with isolated clover isoflavone over a 6-week period lowered PWV in postmenopausal 202 
women and older men [27].   203 
Cherry juice appeared to have no influence on BP in our sample of apparently 204 
healthy middle-aged men and women. There are no directly comparable studies, and those 205 
testing purified anthocyanins and extracts/juices rich in anthocyanins are inconsistent. A 4-206 
wk intervention with a twice-daily supplement of 320 mg of purified anthocyanins failed to 207 
alter BP in middle-aged men with raised baseline BP [28].  Similarly, in elderly women 208 
supplementation with an elderberry extract (500 mg/d of anthocyanins) for 12 weeks failed to 209 
alter BP [29].  However, Chong et al [30] suggested that chokeberries may have hypotensive 210 
effects based on a single intervention study in patients with cardiovascular disease.  211 
We also observed no change in CRP as a result of cherry juice supplementation.    212 
CRP is a recognised biomarker of systemic inflammation and a risk marker for 213 
cardiovascular events [31].   This lack of effect on CRP contrasts with the studies of Kelley et 214 
al. [10, 11] who reported that 280 g/d of sweet cherries (supplying approx. 100 mg/d 215 
anthocyanins) reduced CRP by 8% after 2 weeks of supplementation and by 25% after four 216 
weeks of supplementation. Although these changes in CRP seem to indicate that sweet 217 
cherries elicit a reduction in inflammation, the study lacked a control group so interpretation 218 
must be cautious. Our results also contrast with studies demonstrating that tart cherry juice 219 
attenuates the inflammatory response to marathon running and resistance exercise [12, 13]. 220 
This discrepancy may be explained by differences in dosing schedule (1 serving/d v 2 221 
servings/d) or indicate that in healthy adults, tart cherry juice attenuates the response to an 222 
inflammatory challenge, but does not modulate baseline levels of inflammation.    223 
Cherry juice has potent antioxidant effects [4, 32]. At the end of the current 224 
intervention, plasma antioxidant status (measured by the FRAP assay) was modestly elevated 225 
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in the tart cherry group in comparison to the control group, however, this was largely driven 226 
by a fall in antioxidant status in the control group. This may reflect the displacement of 227 
antioxidant containing beverages by the placebo drink. The FRAP assay probably has limited 228 
sensitivity to detect an increase in antioxidant status in response to the tart cherry juice. The 229 
main determinants of plasma FRAP are uric acid, which may be lowered by cherries and 230 
ascorbate which is only present in low amounts in tart cherry juice [24, 33]. The contribution 231 
of polyphenols to plasma FRAP activity is likely to be low [24].     232 
The inertia in response of total and HDL cholesterol concurs with one short-term 233 
intervention study using sweet cherries [10]. A lack of impact on blood lipids has also been 234 
noted in relation to diet intervention with other anthocyanin-rich berries [30].  235 
The current study has several limitations.   It would have been informative to have 236 
checked compliance to the intervention through measurement of plasma or urinary 237 
anthocyanins.  As an adjunct to this, a detailed dietary record would have been informative as 238 
to any dietary displacement effects. We narrowly failed to meet our recruitment target of 25 239 
participants in each arm. This slightly reduced the power of the study to identify a change in 240 
PWV. For CRP, the low sensitivity of the assay (CV 11.5%) may have masked a small anti-241 
inflammatory effect. All biochemical measures were performed in capillary samples collected 242 
by finger prick. Limited blood volume meant that we failed to collect complete data for some 243 
analytes; this may have contributed to our null effect. It is also possible that our null effect 244 
arose because participants may have been too healthy to detect a beneficial effect of cherry 245 
juice.  We cannot rule out the possibility that cherry juice may be more effective in 246 
individuals with existing hypertension or cardio-metabolic disease.  247 
In conclusion our study provides no evidence that a short-term intervention with tart 248 
cherry juice reduces arterial stiffness or improves other markers of cardiovascular risk in 249 
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apparently healthy adults. Confirmation of this null effect is needed, perhaps using longer 250 
intervention periods and examining individuals at high risk of cardiovascular disease.  251 
 252 
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Table 1 Participant characteristics according to randomisation group at study inclusion (means and SDs)  349 
 Cherry juice (n=25)  Placebo (n=21)   350 
Age (years) 38.3 (6.16) 37.2 (5.78)  351 
Weight (kg) 70.4 (12.75) 69.2 (14.55) 352 
      BMI (kg/m2) 24.6 (3.63) 23.5 (3.00) 353 
      Sex (Female/Male) 16/9 13/8 354 
 355 
 356 
Table 2 Change in outcome variables in the tart cherry juice and control groups over the 6 week intervention period  357 
 358 
 Cherry juice   Placebo   Adjusted  359 
 Baseline End Baseline End difference#   360 
 (mean (SD)) (mean (SD)) (mean (SD)) (mean (SD)) (95% CI)   361 
  362 
PWV (m/s) 8.22 (1.69) 8.18 (1.60) 7.98 (1.21) 7.74 (1.06) 0.243 F (1, 43) =1.564 363 
n 25  21  (-0.149, 0.634) P= 0.218 364 
 16 
hsCRP (mg/L)* 1.13 (0.92, 1.38) 1.13 (0.93, 1.03) 1.14 (0.91, 1.43) 1.26 (1.01, 1.59) -10%**   F (1, 36) = 1.559 365 
n 22  17  (-14%, 7%) P = 0.220 366 
SBP (mm Hg) 110.5 (14.38) 110.2 (12.58) 110.43 (12.28) 113.36 (11.88) -3.21 F (1, 43) = 2.019 367 
n 25  21  (-7.763, 1.346) P = 0.163 368 
DBP (mm Hg) 70.3 (10.04) 69.2 (9.86) 67.4 (8.28) 69.9 (7.62) -2.814 F (1, 43) = 2.496 369 
n 25  21  (-6.406, 0.778) P = 0.121 370 
Cholesterol (mmol/L)  371 
  Total 4.25 (0.79) 4.22 (0.77) 3.76 (0.67) 4.12 (0.67) -0.183 F (1, 40) = 0.926 372 
  n   24  19  (-0.569, 0.202) P = 0.342 373 
  HDL* 0.96 (0.87, 1.05) 1.09 (1.02, 1.16) 1.37 (0.92, 1.15) 1.04 (0.97, 1.11) 7%**  F (1, 36) = 2.436 374 
  n   22  17  (-2%, 16%) P = 0.127 375 
FRAP (µM) 1205 (339.45) 1294 (269.03) 1298 (323.05) 1165 (255.55)  173.58 F (1, 39) = 6.909 376 
  n  23   19  (40.002, 307.159) P = 0.012 377 
 378 
#Effect of intervention was assessed by ANCOVA adjusted for baseline. *Data was log transformed prior to analysis so baseline and end of 379 
study data is expressed as geometric mean and 95% CI. **Adjusted mean difference for log transformed data is expressed as a percentage 380 
(Bland 2000). 381 
